Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Latest "Placebo Hepatitis Virus Infection" News Stories

00:37 EDT 29th July 2014 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 8,000+

Extremely Relevant

[Seminar] Hepatitis B virus infection

Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the world's population show serological evidence of current or past infection. Hepatitis B virus is a partly double-stranded DNA virus with several serological mar...

Hepatitis C Infection May Have 'Silver Lining' for Transplant Patients

WEDNESDAY, June 25, 2014 -- The liver-damaging hepatitis C virus may come with an unexpected benefit for patients who need a liver transplant due to the infection, a new European study reports. The virus appears to restrain a dangerous immune...

Newly found tactics in offense-defense struggle with hepatitis C virus

(University of Washington) The hepatitis C virus (HCV) has a previously unrecognized tactic to outwit antiviral responses and sustain a long-term infection. It also turns out that some people are genetically equipped with a strong countermeasure to...

Quantum Leaps, Microeconomics, and the Treatment of Patients With Hepatitis C and HIV Coinfection

Until very recently, patients with hepatitis C virus (HCV) infection were treated with pegylated-interferon administered weekly by subcutaneous injection plus ribavirin given orally twice daily. Over the last decade, however, by virtue of development...

Ciclofilin developing first drug for HCV/HIV-1 co-infection

Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity directed against both viruses. “Other companies are working on one or the other virus, so we would like to position ourselves as the company working on co-infection, where our […]

Medical News Today: Study identifies global prevalence of hepatitis C virus genotypes

Researchers from the UK have identified the worldwide prevalence of hepatitis C virus genotypes, in the hope it will help develop new treatment strategies for the infection.

Transmission of hepatitis C virus following antiviral treatment

Millions of people throughout the world are infected with hepatitis C virus (HCV). Left untreated, infection results in serious complications such as cirrhosis of the liver and cancer. Many HCV-infected patients respond well to anti-viral therapy and...

Can low-dose interferon prevent relapse of hepatitis C virus infection?

(Mary Ann Liebert, Inc./Genetic Engineering News) Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals. Low-dose o...

CDC Celebrates 25th Anniversary of the Discovery of the Hepatitis C Virus

Twenty-five years ago the Centers for Disease Control and Prevention (CDC) played a pivotal role in the discovery of the virus that causes hepatitis C. After the isolation of HCV, implementation of screening of blood products and organs for donation led to a decrease in rates of HCV infection between 1990 and 2009. In spite of these successes, HCV

Task Force Recommends Screening High-Risk Individuals for Hepatitis B Infection

Individuals who are at high risk of infection with the hepatitis B virus (HBV) should be screened, according to a new recommendation from the US Preventive Services Task Force (USPSTF) (LeFevre ML et al. Ann Intern Med. doi:10.7326/M14-1018 [publishe...

[Comment] QUEST for a cure for hepatitis C virus: the end is in sight

Worldwide, an estimated 170–200 million people have chronic hepatitis C virus (HCV) infection. Successful eradication of HCV has been associated with a reduction in these adverse outcomes. However, less than 50% of people infected with HCV genotype...

Pharma refuses to ensure access to lifesaving Hepatitis C treatment at global meeting

Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies....

Structure of virus identified that could lead to hepatitis C vaccine

Rutgers University scientists have determined the structure of a hepatitis C surface protein, a finding that could assist in the development of a vaccine to halt the spread of the the deadly disease that has infected 3.2 million Americans.Joseph Marc...

Daclatasvir and sofosbuvir (Sovaldi) with and without ribavirin for chronic hepatitis C infection

Daclatasvir in combination with sofosbuvir is intended to be used as first line therapy for the treatment of chronic hepatitis C infection with genotypes 1, 2, and 3. If licensed, this combination will provide an additional treatment option for this patient group, that does not require co-administration with interferon. Daclatasvir is a small molecule hepatitis C virus non-structural 5A (NS5A) rep...

Hepatitis C Virus Therapy in the Direct Acting Antiviral Era

It is possible to cure chronic hepatitis C in the vast majority of patients with this infection and often without interferon. This new study gives us an overview of treatment strategies. Current Opinion in Gastroenterology

One in 100 Americans has chronic hepatitis C infection

NEW YORK (Reuters Health) - At least one percent of Americans are chronically infected with the hepatitis C virus, which over time can severely damage the liver, according to a new study.

Antiviral treatment of hepatitis C

Hepatitis C virus (HCV) infection is a substantial health problem worldwide. Most patients infected with HCV remain chronically infected, with an increased risk of cirrhosis and hepatocellular...

Ordering and interpreting hepatitis B serology

Learning pointsOpportunistic testing for hepatitis B virus (with HBsAg, anti-HBc, and anti-HBs) in people at high risk for hepatitis B virus is essential for diagnosis and appropriate managementMost...

Virus Infection Supports Organ Acceptance

A question of tolerance: Liver transplants in patients with hepatitis C Chronic hepatitis C virus infections are among the most common reasons for liver transplants. Because existing viruses also infect the new liver, the immune system is highly active there. Despite this, the new organ is not rejected, as scientists from the Helmholtz Zentrum München and the Technische Universität M&uum...

Shorter Treatment Strategy Beats Hepatitis C

BOSTON (MedPage Today) -- A 6-week treatment regimen appeared to be as effective as 12 weeks of therapy for patients with hepatitis C virus infection, researchers reported here.

New Expensive Treatments for Hepatitis C Infection

Treatment of infection with hepatitis C virus (HCV) has changed substantially in the last 3 years, with new therapies now reaching cure rates (defined by sustained virologic response) higher than 95%. As little as 3 years ago, treatment involved an a...

[Articles] Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Simeprevir once daily with peginterferon alfa 2a and ribavirin shortens therapy in treatment-naive patients with HCV genotype 1 infection without worsening the adverse event profiles associated with peginterferon alfa 2a plus ribavirin.

Study quantifies prevalence of chronic HCV infection

(HealthDay)—The prevalence of hepatitis C virus (HCV) infection is about 1 percent, with 2.7 million U.S. residents estimated as having chronic HCV infection, according to a study published in the March 4 issue of the Annals of Internal Medicine.

Breaking bad mitochondria: Mechanism helps explain persistence of hepatitis C virus

Researchers at the University of California, San Diego School of Medicine have identified a mechanism that explains why people with the hepatitis C virus get liver disease and why the virus is able to persist in the body for so long.

Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus

(Lifespan) Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection program, states in a commentary in the July, 2014 Rhode Island Medical Journal special edition, 'RI Defeats Hep C' that eliminating hepatitis C virus i...


Search BioPortfolio:
Advertisement
Advertisement

News Quicklinks